164650-44-6

We have more than 10 years of experience in custom synthesis of compounds. If you are looking for a supplier or manufacturer of Efinaconazole (CAS No.:164650-44-6) please contact us. We can provide customers with custom synthesis from grams to kilograms and the production of tons of compounds. Now, we also hope to meet your needs for Efinaconazole (CAS No.:164650-44-6) and other compounds. We can provide high-quality compounds and good service for you.

Send Inquiry

Product Description

Name	Efinaconazole
Synonyms	Efinaconazole [USAN:INN];UNII-J82SB7FXWB;KP-103;(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol;Efinaconazole (JAN/USAN/INN);EFINACONAZOLE;Efinaconazole [INN]
Molecular Formula	C₁₈H₂₂F₂N₄O
Molecular Weight	348.39000
CAS Number	164650-44-6
purity	≥98%
Storage conditions	Sealed in dry,Store in freezer, under -20°C

application：Efinaconazole (trade names Jublia and Clenafin) (CAS No.:164650-44-6) is a triazole antifungal. It is approved for use in Canada and the USA as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail). Efinaconazole acts as a 14α-demethylase inhibitor.
In two clinical trials 17.8% and 15.2% of patients using efinaconazole were cured, compared to 3.3% and 5.5% of patients using a placebo.
Efinaconazole (CAS No.:164650-44-6) is not especially effective, but it is currently the best topical treatment available, with cure rates two or three times better than the next best topical treatment, ciclopirox. It is considered a reasonable option for patients with mild cases, or patients who can not take oral treatment.
In 2014, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for Jublia, the "first topical triazole approved for the treatment of onychomycosis of the toenails." According to Valeant Pharmaceuticals International Inc CEO J. Michael Pearson they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008.

Hot Tags: